Alyeska Investment Group, L.P. Eye Point Pharmaceuticals, Inc. Transaction History
Alyeska Investment Group, L.P.
- $16.5 Billion
- Q2 2024
A detailed history of Alyeska Investment Group, L.P. transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 251,348 shares of EYPT stock, worth $2.01 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
251,348
Previous 147,837
70.02%
Holding current value
$2.01 Million
Previous $3.06 Million
28.45%
% of portfolio
0.01%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding EYPT
# of Institutions
163Shares Held
58.2MCall Options Held
224KPut Options Held
1.41M-
Cormorant Asset Management, LP Boston, MA8.33MShares$66.4 Million5.57% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$41.3 Million1.88% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$30 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.65MShares$29.1 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.59MShares$28.7 Million0.06% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $272M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...